Not two months after getting the FDA nod for its implantable CGM, Eversense, Senseonics held its Q2 earnings call reporting a increase in year over year revenues. However, it continues to operate at a net loss.
“In a matter of just six short weeks, we’ve accomplished a lot. We’ve received the authorization from the agency to commercialize in the US, we launched our US commercial activities...
Senseonics, a Germantown, Maryland-based company working on a longterm implantable continuous glucose monitor, announced preliminary results from its US pivotal trial, a major step toward receiving premarket approval from the FDA, on the same day as the company's second quarter earnings call.
"We are at a significant point of change for not only acceptance and utilization but the recognition by...